Prson Gautam received his MSc degree in Applied Biotechnology at the Uppsala University, Sweden, and completed his PhD at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland in Jan 2018. During his PhD he used chemical systems biology approach to study triple negative breast cancer with an aim to establish precision based therapeutic strategies under the supervision of Prof. Dr. Krister Wennerberg. Currently, he is working 50% as a postdoctoral researcher under supervision of Prof. Dr. Tero Aittokallio at FIMM, University of Helsinki and 50% as global project manager at Bayer. In FIMM, he aims to identify drug or drug combination against pancreatic and breast cancer, applying drug repurposing studies. Besides, he is also involved in multiple bioinformatics project to develop machine learning based predictive models to predict drug/drug combination effects and biomarkers. In Bayer, he is running/managing first in human to phase 3 clinical trials. As a scientist, he has supervised several undergrad and grad students, published more than 15 international research articles and also reviewed several research articles.
